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We examined the effects of essential oil from legal (THC <0.2% w/v) hemp variety on the nervous system in 5 healthy volunteers.
GC/EIMS and GC/FID analysis of the EO showed that the main components were myrcene and 𝛽-caryophyllene. The experiment
consisted of measuring autonomic nervous system (ANS) parameters; evaluations of the mood state; and electroencephalography
(EEG) recording before treatment, during treatment, and after hemp inhalation periods as compared with control conditions.
The results revealed decreased diastolic blood pressure, increased heart rate, and significant increased skin temperature. The
subjects described themselves as more energetic, relaxed, and calm. The analysis EEG showed a significant increase in the mean
frequency of alpha (8–13Hz) and significant decreased mean frequency and relative power of beta 2 (18,5–30Hz) waves. Moreover,
an increased power, relative power, and amplitude of theta (4–8Hz) and alpha brain waves activities and an increment in the delta
wave (0,5–4Hz) power and relative power was recorded in the posterior region of the brain. These results suggest that the brain
wave activity and ANS are affected by the inhalation of the EO of Cannabis sativa suggesting a neuromodular activity in cases of
stress, depression, and anxiety.
1. Introduction
The European Pharmacopoeia, sixth Edition (2007), lists 28
essential oils (EOs) [1]. These oils are employed by inhalation
and dermal (percutaneous absorption) and oral ingestion in
the form of capsules. Industrial hemp (Cannabis sativa L.
cultivars) is cultivated for fiber and seed production, but has
an incredible number of possible applications as ingredient
in the cosmetics industry, as flavouring for beverages (food
industry), and in medicine. Several studies have been carried
out on the cannabinoid content, resin, and seed oil of
Cannabis sativa L. cultivars, but few studies have focused on
the chemical composition and pharmacology of the essential
oil extracted from fresh inflorescences and even fewer studies
are concerned with its possible uses [2–6].
The hemp essential oil is a complex mixture of many
volatile compounds, mainly monoterpenes, sesquiterpenes,
and other terpenoid-like substances [7]. The main chemical
components are myrcene, 𝛽-caryophyllene, limonene, 𝛼-
pinene, 𝛽-pinene, terpinolene, and 𝛼-humulene. The gen-
eral properties of these substances include antidepressant,
relaxant, anxiolytic, sedative, antimicrobial, and antioxidants
[8]. Some researchers studied the antibacterial properties
of this oil. These findings show that industrial hemp EOs
exhibited good antimicrobial activities, with respect to Gram
(+) bacteria such as Enterococcus hirae, Enterococcus faecium,
and S. salivarius subsp. thermophilus and against clostridia
(in this case only C. sativa L. varieties Futura) [9]. The
study of Russo describes pharmacological properties of main
terpenoids present in industrial hemp EOs [8].
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In the research by Bahia et al., they reported that
𝛽-caryophyllene may be useful in treating anxiety and
depression. Moreover they demonstrated the effect of
𝛽-caryophyllene and its underlying mechanism in a
CB2 receptor-dependent manner in mice [10]. These 𝛽-
caryophyllene’s properties may explain why Cannabis users
often cite relief of anxiety and depression as reason for their
use. But, presently, the effects of hemp EOs inhalation on
the brain in humans have not been studied and there are
no studies on the possible therapeutic use. However, these
studies support that hemp EOs inhalation can have a relaxing
effect on the nervous system. Thus, this study is the first
to focus on aspects such as brain wave activity and ANS
parameters such as heart rate, blood pressure, respiratory
rate, and skin temperature, as well as the assessment of mood
states through comparative measures. Moreover gas chro-
matography characterization of hemp EOs was conducted.
2. Materials and Methods
2.1. Essential Oil Analysis. Hexane used for preparing work-
ing solution was purchased from Carlo Erba (Rodano, MI,
Italy), while the linear n-hydrocarbons (C9–C40) were pur-
chased from Sigma-Aldrich.
The EO used in this study is an extract of Cannabis sativa
L. (Cannabaceae; hemp) purchased from Assocanapa Asso-
ciation (Carmagnola, TO, Italy). The EO was obtained from
fresh leaves and inflorescences of Cannabis sativa L. were
collected and steam distilled by Assocanapa Association,
as given by the Italian Official Pharmacopoeia (2,5 L water
distilled, 2 h in Clevenger-type apparatus). The Cannabis EO
(CEO) yield was 0,11% v/w. CEO and EOs dilutions were
stored at 4∘C before use. Gas chromatography/electronic
ionization mass spectrometry (GC/EIMS) and gas chro-
matography/Flame Ionization Detector (GC/FID) analyses
were accomplished using an HP-5890 Series II instrument
equipped with HP-WAX and HP-5 capillary columns (30 𝜇m
× 0.25mm, 0.25 𝜇m film thickness), detector dual FID,
working with the following temperature programme: 60∘C
for 10min, ramp of 5∘C/min to 220∘C; injector and detector
temperatures 250∘C; carrier gas nitrogen (2ml/min); detector
dual FID; split ratio 1 : 30; injection of 0.5𝜇l. For both
columns, components were identified by comparing their
retention times with those of pure authentic samples and by
means of their linear retention indices (l.r.i.) [11, 12] relative to
the series of n-hydrocarbons. The relative proportions of the
EO constituents were percentages obtained by FID peak-area
normalization, all relative response factors being taken as one.
GC/EIMS analyses were performed with Varian CP-3800
gas chromatograph (Variant, Inc. Palo Alto CA) equipped
with aDB-5 capillary column (Agilent Technologies Hewlett-
Packard, Waldbronn, Germany, 30m × 0.25mm; coating
thickness 0.25𝜇m) and a Varian Saturn 2000 ion trap mass
detector. Analytical conditions were as follows: injector and
transfer line temperatures 220 and 240∘C, respectively; oven
temperature programmed from 60 to 240∘C at 3∘C/min;
carrier gas helium at 1ml/min; injection of 0.2𝜇l (10% hexane
solution); split ratio 1 : 30. Identification of constituents was
based on comparison of the retention times with those of
authentic samples, comparing their l.r.i. relative to the series
of n-hydrocarbons (C9–C40), and on computer matching
against commercial (NIST 98 and ADAMS 95) and home-
made library mass spectra built up from pure substances and
components of known oils and MS literature data [13, 14].
The percentage compositions were computed from the
GC peak areas. Moreover, the molecular weights of the all
identified substances were confirmed by GC/CIMS, using
MeOH as CI ionizing gas. Analysis of the essential oils
identified 35 constituents (Table 1), accounting for 97.6%
of the total oils (only compounds >0,1% are reported in
Table 1). Monoterpene hydrocarbons represented the 57.2%
of total volatiles and myrcene was the main constituent
(22.9%). Sesquiterpenes hydrocarbons represented the sec-
ond class of volatiles (34.3%) with the most abundant being
𝛽-caryophyllene (18.7%).
2.2. Subjects. Five healthy volunteers (3 males and 2 females)
aged 30 to 57 years (mean age 40,8 ± 12,19 years) and
with body mass index (BMI) between 19,05 and 34,60 kg/m2
(mean BMI 26,986 ± 7,18 kg/m2) participated in this study.
Demographic data of the participants is presented in Table 2.
Only five volunteers were available for the experimental ses-
sion preprogrammed; other recording experimental sessions
were not made because environmental parameters would not
be reproducible and comparable. None of the subjects had
cardiovascular disease, they did not exhibit any symptoms
of upper respiratory infection, and women were not to be in
their menstrual period on the day of the tests. Two subjects
were smokers and one of the male subjects had a slight
headache at the time of the experiment. All experimental
procedures were followed with the strict ethical standards
formulated in the Helsinki Declaration of 1964 that was
revised in 2000 and all the subjects have participated in
the study after signing the informed consent. The study was
conducted in private healthcare facilities outside the network
of the Regional Health System. Therefore, any ethical and
managerial assumption is rooted in the direct relationship
between the patient, who has released the relative consent,
and the host structure.
2.3. Methods. One milliliter of sweet almond oil (SAO, base
oil, purchased from Carlo Erba) was used for control condi-
tion as placebo and one milliliter of CEO was administered
according to the protocol described in Figure 1. The sweet
almond oil was administered with gauze and participants
were asked to inhale simultaneously with both nostrils. The
same procedure was also adopted for the CEO. In accordance
with previous studies, it has been found that the pleasantness
of the aroma of the oil could alter autonomic activity [15, 16].
As a result of these facts, the subjects were asked to inhale
SAO and CEO to assess the pleasantness or less pleasantness
of the aroma.
2.4. ANS and Mood State Measurement. Themood state and
ANS parameters of the subjects such as blood pressure, heart
rate, skin temperature, and respiratory rate were recorded
simultaneously. The ANS parameters were measured manu-
ally. While the evaluation of the changes of moods was made
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Table 1: GC-MS results of the essential oil extracted from hemp
inflorescences (Cannabis sativa L. var. monoica).
Constituents l.r.i.∧ Percentage
𝛼-Pinene 941 7,7
Camphene 955 0,2
Sabinene 978 0,2
𝛽-Pinene 982 3,7
Myrcene 993 22,9
𝛼-Phellandrene 1007 0,3
𝛿-3-Carene 1010 0,6
𝛼-Terpinene 1020 0,3
p-Cymene 1028 0,5
Limonene 1033 3,9
1,8-Cineole 1035 0,2
(𝑍)-𝛽-Ocimene 1042 0,7
(𝐸)-𝛽-Ocimene 1053 3,9
𝛾-Terpinene 1063 0,3
Terpinolene 1090 12,0
Linalool 1101 0,3
p-Cymen-8-ol 1184 0,5
𝛼-Terpineol 1192 0,2
Carvacrol 1301 0,2
(𝑍)-Caryophyllene 1406 0,7
𝛽-Caryophyllene 1419 18,7
trans-𝛼-Bergamotene 1438 1,5
𝛼-Humulene 1455 6,2
9-epi-Caryophyllene 1468 2,3
𝛾-Muurolene 1478 0,2
𝛽-Selinene 1487 1,6
𝛼-Selinene 1495 1,5
𝛽-Bisabolene 1508 0,4
trans-𝛾-Cadinene 1514 0,2
𝛿-Cadinene 1524 0,2
Selina-3,7(11)-diene 1544 0,6
Germacrene B 1557 0,2
Caryophyllene oxide 1582 3,7
Humulene oxide II 1607 1,0
Monoterpene hydrocarbons 57,2
Oxygenated monoterpenes 1,4
Sesquiterpene hydrocarbons 34,3
Oxygenated sesquiterpenes 4,7
Total identified 97,6
Percentages are obtained by FID peak-area normalization, all relative
response factors being take as one (HP-5) column. Mean of three analy-
ses. ∧Linear retention indices (HP-5 column) relative to the series of n-
hydrocarbons.
through a subjective evaluation of the participants using a list
of 8 terms selected for their relevance to describe affective
feelings induced by odors and mood state after inhalation of
CEO: anxiety, calm, hungry, hilarity, fatigue, apathy, energy,
and heavy eye [17–19].
2.5. EEG Recording. A set of 21 electrodes with an additional
ground electrode and a reference electrode were placed
onto the subject’s head with electrocap in accordance with
the international 10–20 system at F1, F2, F7, F3, Fz, F4,
F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, and O2.
Mizar 40 EBNeuro-Firenze was used as the recording system.
Sampling rate was set at 512Hz; the HF filter was set at
70Hz; time constant 0,3; range −/+4,1mV.The relative power
spectrum of the respective frequency bands was expressed
as follows: delta (0,5–4Hz), theta (4–8Hz), alpha (8–14Hz),
and beta (14–30Hz). Furthermore, the beta wave was further
categorized as beta 1 or low frequency beta (14–18Hz) and
beta 2 or high frequency beta (18,5–30Hz) activities.
2.6. Experimental Protocol/Procedure. All the steps in this
experiment were similarly conducted as the previous study
recorded on the effects of rosemary oil inhalation [20]. All
activities were conducted in a quiet room and the subjects
were seated in a comfortable chair. The ANS electrodes were
attached to the appropriate positions. The ANS parameters:
heart rate, skin temperature, respiratory rate, and systolic and
diastolic blood pressure were recorded at the beginning of the
experiment before resting (baseline) EEG measurement and
after CEO inhalation.
The experiment consisted of three trials: first session
served as a baseline (resting period) and took ten minutes.
The second and the third sessions took five minutes each.
The first session baseline EEG recording was done with
both eyes opened and eyes closed, respectively. In the second
session, SAO was inhaled by the subjects. In the third
session, CEO was applied and mood state was measured
after inhalation. EEG was recorded for five minutes during
SAO inhalation and after five minutes of rest it was recorded
again for five minutes during CEO inhalation. After the
recordings, the subjects were asked to give their preference
and impression of the odors presented and of their moods
(Figure 1).
2.7. Statistical Analyses. The MedCalc statistics for biomedi-
cal research software version 16.2.1 was done for data analysis
of the effects of CEO on physiological reactions and mood
states, before and after the hemp inhalation. A nonparametric
Kruskal Wallis signed rank test was used for EEG data
analysis and Friedman test was performed to determine
whether the activity changed significantly in any of frequency
bands in P4-O2 and P3-O1 brain region. A paired 𝑡-test was
carried out on data concerning the subjects’ blood pressures,
heart rates, skin temperatures, and respiratory rates. A𝑝 value
< 0,05 was considered significant. A percentage evaluation
was done for the mood states.
3. Results and Discussion
In the present research, CEO was administered by inhalation
to healthy subjects and we examined the effects of the oil
on the human nervous system. Brain wave activity and ANS
parameters (blood pressure, heart rate, respiratory rate, and
skin temperature) were recorded as the indicators of the
arousal level of the nervous system. In addition, we studied
the effects of CEO on moods by performing subjective self-
evaluation in order to assess the arousal levels.
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Table 2: Demographic data for subjects.
Parameters Subjects (
∗M, ∗F) Minimum Maximum Mean SD
M1 M2 M3 F1 F2
Age 57 30 50 30 37 30 57 40,8 12,19
Weight (Kg) 90 100 95 55 50 50 100 78 24,04
Height (cm) 176 170 172 165 162 162 176 169 5,56
BMI (Kg/m2) 29,05 34,6 32,11 20,2 19,05 19,05 34,6 26,996 7,18
∗M: Male; ∗F: Female.
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Figure 1: Experimental protocol of EEG, ANS, and mood states measurements divided into 8 blocks: ANS parameters recording; EEG
recording in baseline condition (10min), EEG in placebo condition (1ml sweet almond oil inhalation, 5min); pause (5min); EEG Cannabis
EO inhalation (1ml, 5min); pause (5min); ANS parameters recording; and finally mood states measurement.
3.1. Autonomics Nervous System Parameters. Inhalation of
CEO has been correlated with changes in ANS parameters
and skin temperature significantly increased (p < 0,05). The
data of various ANS parameters were compared during rest
(control) and CEO inhalation as shown in Table 3. In 60%
of subjects heart rate had increased during CEO exposure.
In contrast, diastolic blood pressure had decreased in 80% of
subjects. But these data did not reach statistical change.These
changes of the ANS parameters indicated an involvement of
the autonomic nervous system and parasympathetic nervous
system (PNS). The stimulatory effects on the ANS and PNS
may be explained through the presence of monoterpenes
(limonene and 𝛼-pinene) that are present in CEO.
The 𝛼-pinene inhibits acetylcholinesterase [21], which
results in the activation of the PNS, and this might be respon-
sible for the reduction in diastolic blood pressure. While the
stimulatory effects on the sympathetic system determined by
limonene might be responsible for the increase in heart rate
and skin temperature [22].
3.2. Emotional Parameters. All subjects found theCEOpleas-
ant. The alterations of mood states after exposure to CEO
are shown in Table 4. The subjects felt more calm, relaxed,
and energetic, were in a good mood, and had increased
feeling of hunger and the subject with headache had no more
pain.These results indicate that CEO inhalation increases the
level of relaxation and general well-being as assessed through
our test subjects’ self-evaluation.This relaxing and anxiolytic
effect on ANS could be explained by the abundance of
limonene, myrcene, and 𝛽-caryophyllene, main components
of the EO. Several studies in animals and humans suggest that
the limonene can be a powerful anxiolytic agent via 5-HT.
Also, limonene demonstrated antistress effects on the brain
of rats. Bahia and colleagues found that b-caryophyllene has
an anxiolytic and antidepressant activity in a CB2 receptor-
dependent manner [10, 22].
Myrcene, the main component of CEO, has a sedative,
analgesic, and relaxing activity [23, 24]. Thus, these results
confirm that CEO contains mood-elevating bioactive com-
ponents that prove to be beneficial to its users.
3.3. EEG Parameters. EEG spectral analysis was done with
quantitative evaluation of windows on 2 seconds with Inter-
polation Algorithm Rectangular.
Five frequency bands were evaluated (delta, theta, alpha,
beta 1, and beta 2) and values of power (𝜇V2), amplitude
(𝜇V), relative power (𝜇V2), and mean frequency were calcu-
lated during rest, during SAO inhalation, and during CEO
inhalation states. The studied areas were divided into the
right posterior area (P4-O2) and left posterior area (P3-O1)
brain regions.The data recording shows an alteration of EEG
during exposure to the CEO. There were noticeable changes
of band power, amplitude, and relative power in alpha, theta,
delta, and beta waves as reported in Tables 5, 6, 7, and 8 (mean
and median value).
During the CEO inhalation the power, the relative power,
and amplitude of the alpha waves in both brain regions
were increased and mean frequency for alpha significantly
increased (compared with SAO) in P4-O2 brain area (p <
0,05). The power and relative power changes in the theta
and delta waves in the left posterior brain region were also
increased. In contrast, the power in the delta wave in the
right posterior brain region was decreased. A significant
decrease was observed in the case of the beta 2 wave’s
relative power (compared with resting condition) and mean
frequency (compared with SAO) in P4-O2 (p < 0,05), Figures
2 and 3. The present research shows the effects of CEO
inhalation on brain waves. This research showed that alpha
(8–13Hz) and theta (4–8Hz) activity increased during CEO
exposure in the posterior regions, and mostly left posterior
area P3-O1 brain regions. Moreover, alpha mean frequency
increased significantly in P4-O2 region. These results show
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Table 5: Mean andmedian power values and 𝑝 value for resting condition, sweet almond oil inhalation, and cannabis essential oil inhalation.
Brain area Resting Sweet almond oil Cannabis essential oil 𝑝 value
Theta power (𝜇V2)
P4-O2 3,286 (2,77) 3,704 (2,75) 3,366 (3,36) 0,268
P3-O1 3,166 (3,19) 3,522 (3,16) 7,776 (5,21) 0,497
Alpha power (𝜇V2)
P4-O2 41,266 (38,95) 48,592 (39,41) 58,788 (40,17) 0,599
P3-O1 46,698 (48,45) 36,8 (30,88) 51,036 (51,26) 0,268
Delta power (𝜇V2)
P4-O2 10,734 (4,68) 18,96 (12,23) 15,36 (15,72) 0,167
P3-O1 8,768 (8,4) 13,756 (8,14) 19,542 (17,09) 0,268
Beta 1 power (𝜇V2)
P4-O2 5,816 (4,61) 8,778 (5,53) 9,05 (7,12) 0,849
P3-O1 6,402 (8,19) 8,01 (7,61) 8,268 (8,4) 0,849
Beta 2 power (𝜇V2)
P4-O2 3,086 (4,05) 2,47 (3,08) 2,83 (3,1) 0,268
P3-O1 2,714 (2,64) 2,918 (2,3) 3,734 (4,14) 0,849
SAO: sweet almond oil; CEO: cannabis essential oil.
Table 6: Mean and median relative power values and 𝑝 value for resting condition, sweet almond oil inhalation, and cannabis essential oil
inhalation.
Brain area Resting Sweet almond oil Cannabis essential oil 𝑝 value
Theta PotR
P4-O2 5,082 (4,06) 5,048 (4,61) 4,642 (3,78) 0,268
P3-O1 5,01 (5,53) 5,386 (5,67) 7,248 (6,32) 0,497
Alpha PotR
P4-O2 65,098 (69,39) 58,608 (60,74) 60,042 (63,23) 0,497
P3-O1 67,488 (68,22) 55,212 (56,46) 55,746 (50) 0,268
Delta PotR
P4-O2 15,64 (14,32) 22,254 (24,25) 21,284 (25,16) 0,497
P3-O1 13,234 (13,36) 21,606 (20,48) 23,34 (25,39) 0,497
Beta 1 PotR
P4-O2 8,224 (8,4) 9,444 (7,98) 9,09 (9,89) 1,00
P3-O1 9,106 (7,57) 12,054 (8,59) 8,318 (9,4) 0,849
Beta 2 PotR
P4-O2 4,482 (2,97) 3,028 (2,82) 3,432 (2,48) 0,05308∗
P3-O1 3,986 (2,84) 4,226 (3,89) 3,862 (3,54) 0,849
SAO: sweet almond oil; CEO: cannabis essential oil. ∗CEO differs from resting with 𝑝 value < 0,05.
concordance with the past EEG studies on the effects of odors
which demonstrated increased alpha activity by administra-
tion of several EOs such as lavender, chamomile, 𝛼-pinene,
and limonene oil [25–28]. Instead alpha activity is attenuated
under emotional tension and stress condition [29].
The EEG evidence of relaxation can be seen in various
practices such as meditation, yoga, Qigong, and mindfulness
[30, 31].The study among peoplemeditating can demonstrate
similar EEG changes with CEO inhalation, which presented
as increase in theta and alpha activities in the brain during
meditation [32, 33]. In addition, the studies of Aftanas [34–
37] show that during meditation there is also release of
hormones such as melatonin, serotonin, and cortisol. These
results lend support that increases in theta and alpha waves
activity cause a range of general relaxation and anxiolytic
effects on the brain and also some possible decreases of
pain. Thus, the data recorded after CEO inhalation shows
relaxation and anxiolytic effects on the brain at level of the
ANS, CNS, and mood states. At level of mood states a feeling
of calm, relaxation, and decreased anxiety was recorded
indicating the involvement of the limbic system.
The changes in ANS parameters (heart frequency, skin
temperature, and diastolic blood pressure) can be explained
by the 𝛼-pinene activity on the parasympathetic system
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Table 7: Mean and median amplitude power values and 𝑝 value for resting condition, sweet almond oil inhalation, and cannabis essential oil
inhalation.
Brain area Resting Sweet almond oil Cannabis essential oil 𝑝 value
Theta Amp
P4-O2 3,11 (2,89) 3,336 (3,06) 3,142 (3,12) 0,268
P3-O1 3,082 (3,13) 3,234 (3,18) 4,066 (3,99) 0,497
Alpha Amp
P4-O2 10,574 (10,06) 10,104 (9,63) 11,204 (10,07) 0,599
P3-O1 10,614 (10,37) 8,88 (8,4) 10,872 (11,65) 0,073
Delta Amp
P4-O2 4,312 (3,63) 5,564 (5,25) 5,45 (5,55) 0,073
P3-O1 4,148 (4,4) 5,246 (4,43) 6,06 (5,53) 0,167
Beta 1 Amp
P4-O2 4,946 (4,76) 5,32 (5,2) 5,548 (5,87) 0,599
P3-O1 5,06 (5,85) 5,37 (6,07) 5,592 (6,36) 0,849
Beta 2 Amp
P4-O2 3,526 (4,14) 3,296 (3,76) 3,458 (3,72) 0,268
P3-O1 3,408 (3,56) 3,432 (3,56) 3,838 (4,28) 0,958
SAO: sweet almond oil; CEO: cannabis essential oil.
Table 8: Mean and median mean frequency values and 𝑝 value for resting condition, sweet almond oil inhalation, and cannabis essential oil
inhalation.
Brain area Resting Sweet almond oil Cannabis essential oil 𝑝 value
Theta Mean𝐹
P4-O2 5,854 (5,83) 5,772 (5,78) 5,732 (5,84) 0,497
P3-O1 5,906 (5,930) 5,848 (5,89) 5,82 (5,94) 0,849
Alpha Mean𝐹
P4-O2 9,982 (9,99) 10,274 (10,28) 10,094 (10,04) 0,00066∗
P3-O1 9,984 (9,96) 10,178 (10,13) 10,026 (9,84) 0,268
Delta Mean𝐹
P4-O2 1,572 (1,61) 1,464 (1,41) 1,474 (1,3) 0,849
P3-O1 1,452 (1,46) 1,428 (1,48) 1,508 (1,38) 0,958
Beta 1 Mean𝐹
P4-O2 14,182 (14,3) 13,89 (14,16) 14,092 (14,58) 0,167
P3-O1 14,026 (14,19) 14,082 (14,34) 14,256 (14,52) 0,599
Beta 2 Mean𝐹
P4-O2 20,026 (20,07) 20,592 (20,57) 20,266 (20,31) 0,00332∗
P3-O1 20,34 (20,55) 20,348 (20,54) 19,982 (19,91) 0,0731
SAO: sweet almond oil; CEO: cannabis essential oil. ∗CEO differs from SAO with 𝑝 value < 0,05.
and limonene activity on the sympathetic system action.
Komiya et al. [22] found that limonene increases serotonin
in the prefrontal cortex, and dopamine (DA) in hippocampus
mediated via 5-HT1A.This determines the direct activation of
the sympathetic system. At levels of CNS activity, alpha and
theta waves increased indicating a relaxing effect and antide-
pressant and antianxiety effect due to the 𝛽-caryophyllene
and limonene. The analgesic action of CEO on the subject
with headache may be explained by increase of alpha and
theta waves and abundance of terpenes such as myrcene,
limonene, and 𝛽- caryophyllene.
4. Conclusions
Thesmall study population is a limitation of this study but it is
however a preliminary study. Further studies of the effect of
CEO on the brain are needed with a wider sample in order
to have a greater number of significant data. However, the
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Figure 2: Each panel shows the mean of power, relative power, mean frequency, and amplitude values of alpha and theta activities for the
resting and sweet almond oil (SAO) and cannabis essential oil (CEO) inhalation states. The theta and delta waves increased mostly in P3-O1.
results lend some support for including CEO in a perspective
integrated therapy aimed at relieving stress or depression.
The results suggest the occurrence of the positive relax-
ation and anxiolytic effects of CEO. These findings provide
evidence that brain wave activity autonomic nervous system
response and mood states were affected by CEO.
Abbreviations
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CNS: Central nervous system
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